SCOPE OPHTHALMICS – LIFTING THE LID ON OCULAR SURFACE DISEASES AT OPTRAFAIR, April 18-20th 2015
- SCOPE ophthalmics partners with leading Optometrists Ian Cameron, Dr. Scott Mackie & Sarah FarRant to host educational workshops at optrafair, 2015
- Scope launches Tranquileyes, a new innovation in dry eye management
[BIRMINGHAM, 18th – 20th April 2015] Scope Ophthalmics, a leading player in the UK ocular surface disease market will be attending the trade show, OptraFair - 18 to 20 April – to provide educational workshops around dry eye disease and blepharitis, and showcase their latest innovation in dry eye disease management, TranquileyesTM.
EXPERT EDUCATIONAL EVENTS
- 1. Everything you need to know about Omega 3 in 30mins
Speaker: Ian Cameron, Optometrist, DipTP (IP)
In this 30 minute session Optometrist Ian Cameron will provide a detailed presentation into the benefits of Omega 3 in treating a range of ocular conditions, the language used to talk about it, and how to convey this to patients concisely.
- Day: Saturday, 18th April
- Time: 1pm – 1:30pm
- Location: Stand L30
Supported by Scope Ophthalmics.
- 2. Demodex Blepharitis: At the route of the problem
Speakers: Dr. Scott Mackie, Consultant Optom. DIP Tp (IP), Cataract & Refractive Surgeon and Sarah Farrant; BSc MCOptom Dip TP(AS)
This interactive workshop will cover new approaches and clinician-performed treatments to successfully manage blepharitis and demodex mite infestation. Video footage from the presenters practice and real life demonstrations using BlephEx™ - the first and only clinician treatment for blepharitis - will help delegates understand the key clinical signs and the latest treatments. Blepharitis is an inflammation of the eyelids and affects one in three people in the UK (NHS Choices UK, 2015). By breaking the cycle of blepharitis, the procedure directly removes the inflammatory exotoxin-laden biofilm. This is a well-tolerated procedure that takes 6 – 8 minutes and repeated every 4 – 6 months.
- Date: Sunday, 19th April
- Time: 1.30pm – 2pm
- Location: Stand L30
Supported by Scope Ophthalmics.
“These workshops are being held as part of Scope Ophthalmics’ consistent focus on education as a cornerstone of our customer service for 2015 and beyond,” explains Tom Freyne, Commercial Director at Scope Ophthalmics. “We’re proud to be working with such prominent experts to help raise the issue of ocular surface diseases.”
New product launch: TranquileyesTM
Scope will showcase their latest product, TranquileyesTM, at OptraFair 2015. Using specially-designed goggles, warm water and reusable gel pack technology; TranquileyesTM enables patients to create a safe, soothing, moist-heat compress; an alternative to dry heat products. Moist heat loosens the oils in the meibomian glands, penetrating deeply to help hydrate the eyelid and surrounding skin, and promote circulation. By contrast, dry heat pulls moisture away from the eyelid and the sensitive surrounding skin, negating the anti-aging requirements of many women, and increasing the instability of the tear film.
Studies1 have shown that applying effective moist heat to the eyelids is beneficial for all levels of meibomian gland dysfunction (MGD).
Tom Freyne, Commercial Director at Scope Ophthalmics explains, “Tranquileyes™ will provide eye care practitioners with a more sophisticated way to help people affected in the UK manage their dry eye or MGD. This is a growing market as our population ages, so it’s important to be able to offer a good range of choice in terms of safe and effective innovations.”
Tranquileyes™ is available as: Instants (travel use), Beads (home use), and Advanced (hybrid). Price from £29.99 RRP.
Available from Scope Ophthalmics. Free phone 0800 270 0253 / www.ScopeHealthcare.co.uk
~ENDS~
For all enquiries, including interview opportunities, please contact:
Beth Lowes at ROAD Communications, beth@ROADCommunications.co.uk
Tel: 44 (0)20 8995 5832
BACKGROUND INFORMATION
Dry Eye Disease (DED) can affect people of any age, although risk increases with age. It is estimated that up to one in every three people over the age of 65 experiences problems with dry eyes, according to NHS Choices2. MGD is thought to be the leading cause of dry eye disease; a chronic disease, it is usually caused by obstruction of the secretory meibomian glands. The subsequent reduction of gland secretion results in a decreased amount of lipids in the tear film. This results in faster evaporation of the tear film and thus an evaporative dry eye. MGD alone is responsible for about 60% of all cases, in combination with aqueous deficiency for a further 20% of dry eyes3.
Scope Ophthalamics is an innovative and fast-growing optical company offering dry eye and blepharitis products in the UK and Ireland. All of its products have had long-term success with patients worldwide. Key product focuses include preservative-free eye drops which contain the ingredient hyaluronic acid. In 2014, Scope successfully launched BlephEx™ as the first and only clinician treatment for blepharitis. The company maintains a major focus on training, customer service, innovation and relationships with key opinion leaders.
Tags:
